Media stories about CareDx (NASDAQ:CDNA) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.7545890719648 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of equities analysts have issued reports on CDNA shares. ValuEngine cut shares of CareDx from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of CareDx in a research note on Wednesday, January 31st. Finally, Zacks Investment Research cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $8.65.
Shares of CareDx (CDNA) traded up $0.01 during mid-day trading on Wednesday, reaching $5.76. 30,000 shares of the company’s stock were exchanged, compared to its average volume of 193,581. CareDx has a 1 year low of $0.76 and a 1 year high of $7.98. The company has a market capitalization of $165.90, a PE ratio of -3.18 and a beta of 0.72. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact CareDx (CDNA) Stock Price” was reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-caredx-cdna-stock-price/1925887.html.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.